Your browser doesn't support javascript.
loading
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Mellinghoff, Ingo K; Penas-Prado, Marta; Peters, Katherine B; Burris, Howard A; Maher, Elizabeth A; Janku, Filip; Cote, Gregory M; de la Fuente, Macarena I; Clarke, Jennifer L; Ellingson, Benjamin M; Chun, Saewon; Young, Robert J; Liu, Hua; Choe, Sung; Lu, Min; Le, Kha; Hassan, Islam; Steelman, Lori; Pandya, Shuchi S; Cloughesy, Timothy F; Wen, Patrick Y.
Afiliação
  • Mellinghoff IK; Department of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. mellingi@mskcc.org.
  • Penas-Prado M; Neuro-oncology Branch, NIH, NCI, Bethesda, Maryland.
  • Peters KB; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
  • Burris HA; Sarah Cannon Research Institute, Nashville, Tennessee.
  • Maher EA; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Janku F; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cote GM; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • de la Fuente MI; Department of Neurology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Clarke JL; Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California.
  • Ellingson BM; UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Chun S; Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, California.
  • Young RJ; Neuroradiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Liu H; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Choe S; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Lu M; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Le K; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Hassan I; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Steelman L; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Pandya SS; Agios Pharmaceuticals, Inc., Cambridge, Massachusetts.
  • Cloughesy TF; Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, California.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Clin Cancer Res ; 27(16): 4491-4499, 2021 08 15.
Article em En | MEDLINE | ID: mdl-34078652
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Neoplasias Encefálicas / Diaminas / Glioma / Isocitrato Desidrogenase / Mutação / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Neoplasias Encefálicas / Diaminas / Glioma / Isocitrato Desidrogenase / Mutação / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article